Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Wednesday Trading

<< Previous

Bullboard Posts

Next >>

Comment by nodaytraderon Dec 20, 2021 3:05pm

85 Views

Post# 34247908

RE:RE:Wednesday Trading

Follow the trades on www.thecse.com (search for AGN)
You will see, almost invariably, following positive news from the company or where the outloo is generally positive, that the market price is driven down by small sales - usually involving the same players.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?